Reneo Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
OKUR$3.39+6.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(In thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(8,426) | $(15,107) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 1,078 | 1,157 |
| Depreciation and amortization | 16 | 41 |
| Amortization/accretion on short-term investments | (906) | (770) |
| Changes in the fair value of performance award | — | 295 |
| Non-cash lease expense | 67 | 120 |
| Loss on disposal of fixed asset | 16 | 3 |
| Changes in operating assets and liabilities: | ||
| Prepaid and other assets | 2,584 | 1,952 |
| Accounts payable and accrued expenses | (15,363) | 3,398 |
| Operating lease liabilities | (80) | (137) |
| Net cash used in operating activities | (21,014) | (9,048) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | — | (172) |
| Purchase of available-for-sale short-term investments | (45,243) | (28,321) |
| Proceeds from maturities of available-for-sale short-term investments | 59,000 | 47,000 |
| Net cash provided by investing activities | 13,757 | 18,507 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock under the at-the-market facility, net of offering costs | — | 1,009 |
| Net cash provided by financing activities | — | 1,009 |
| Net (decrease) increase in cash and cash equivalents | (7,257) | 10,468 |
| Cash and cash equivalents, beginning of period | 27,632 | 19,927 |
| Cash and cash equivalents, end of period | $20,375 | $30,395 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.